Treatment for specific types of pediatric and young adult leukemia using engineered T cells

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 clinical trial evaluates the efficacy of CART19, a type of engineered T cell therapy, in pediatric and young adult patients with specific high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The study consists of four cohorts targeting patients with hypodiploid B-ALL, those with the t(17;19) chromosomal translocation, infants with very high-risk KMT2A B-ALL, and patients experiencing central nervous system relapse without prior cranial radiation or bone marrow transplantation. Participants will receive murine CART19 therapy, and the study aims to assess treatment outcomes in these vulnerable populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed informed consent form must be obtained prior to any study procedure.
2. Male and female patients with documented CD19+ B-ALL

   a.Cohort A \& B: Patients, regardless their response to initial or relapsed B ALL therapy, with the following characteristics: i.Cohort A: Subjects with confirmation of a hypodiploid karyotype (chromosome number fewer than 45) ii.Cohort B: Subjects with cytogenetic confirmation of the chromosomal translocation t(17;19) (Cohort B) b.Cohort C: Infants w/ newly diagnosed KMT2A rearranged B-ALL classified as very high risk by the following criteria: i.Age \< 3 months at diagnosis ii.Age \< 6 months and WBC \> 300,000x109/L at diagnosis or a poor prednisone response in induction iii.MRD positive \> 0.01 (or PCR \> 104) after 2 courses of standard infant ALL therapy.

   c.Cohort D: Subjects in a first or greater CNS relapse, prior to therapy with cranial XRT or HSCT for the current relapse
3. Documentation of CD19 tumor expression in bone marrow, peripheral blood, CSF, or tumor tissue.
4. Age 0 to 29 years
5. Adequate organ function defined as:

   1. A serum creatinine based on age/gender as follows:

      Maximum Serum Creatinine (mg/dL) Age Male Female 0 to \< 2 years 0.6 0.6 2 to \< 6 years 0.8 0.8 6 to \< 10 years 1.0 1.0 10 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4

      ≥ 16 years 1.7 1.4
   2. Adequate liver function:

   i.ALT≤ 5 x ULN; ALT ii.Total bilirubin ≤ 3 x ULN iii.ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver.

   c.Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and \< Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the physician-investigator.

   d.Left Ventricular Shortening Fraction (LVSF) ≥ 28%, or Left Ventricular Ejection Fraction (LVEF) ≥ 45% by echocardiogram. In cases where quanitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualititatively normal ventricular function wll suffice.
6. Adequate performance status defined as Lansky or Karnofsky score ≥ 50
7. Subjects of reproductive potential must agree to use acceptable birth control methods

Exclusion Criteria:

1. For subjects with a CNS relapse, prior cranial XRT or BMT for the current relapse is an exclusion.
2. Active hepatitis B or active hepatitis C.
3. HIV Infection.
4. Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.
5. Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.
6. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
7. Pregnant or nursing (lactating) women.
8. Uncontrolled active infection.

Where it's running

• Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Amanda DiNofia, MD — Children's Hospital of Philadelphia
• Study coordinator: CART Nurse Navigator
• Email: CARTNurseNavigator@chop.edu
• Phone: 445-942-5891

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nature-based program feasibility in preschools near public housing

  This feasibility study tests whether a nature-based program in preschools near public housing can be run smoothly and whether families will participate and benefit.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Frederiksberg · NCT07780123

• Comparing two ultrasound methods for femoral artery access in children

  This trial tests whether a modified ultrasound technique helps anesthesia residents place femoral arterial lines faster and with fewer attempts in infants and children having heart surgery.

  Recruiting American University of Beirut Medical Center · Beirut · NCT07059624

• Optimizing therapy components for pediatric PTSD with a multiphase design

  This project will try different therapy pieces to see which combinations help children and teens (ages 8–17) with PTSD feel better.

  Recruiting University of Rochester · Rochester, New York · NCT06956781

• Registry of long-term outcomes for children after cardiac arrest

  This study is looking at the long-term health and recovery of children in the Netherlands who have had a cardiac arrest to see how well they do after treatment.

  Recruiting at 7 sites Erasmus Medical Center · Nijmegen, Gelderland and 6 other locations · NCT06938009

• Evaluating sedation effectiveness with dexmedetomidine in children undergoing brain MRI

  This study is testing if a nasal spray of dexmedetomidine can safely and effectively help children aged 12 months to 18 years relax during a brain MRI.

  Recruiting Centre Hospitalier Régional Metz-Thionville · Metz · NCT06867289

• Pediatric eCART: an electronic tool to spot children at high risk of critical illness

  This project will test whether implementing pediatric eCART, an EHR-based risk alert system, helps identify hospitalized children at high risk of life-threatening deterioration and is acceptable to pediatric nurses.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT06771830

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.